Artivion (NYSE:AORT) Releases Earnings Results, Beats Estimates By $0.14 EPS

06 Nov 2026, 23:10 by Amy Steele · The Cerbat Gem

Artivion (NYSE:AORT – Get Free Report) issued its earnings results on Thursday. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.14, FiscalAI reports. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. The company had revenue of $123.79 million for the quarter, compared to the consensus estimate of $120.97 million.

Here are the key takeaways from Artivion’s conference call:

Third-quarter revenue grew 9% year over year in constant currency, led by 12% growth in stent grafts and 13% growth in On-X valves. Management said On-X supply has improved after manufacturing investments, while acknowledging that adjusted EBITDA fell 8% and gross margin declined.
Artivion narrowed its 2026 outlook to 8%–10% adjusted constant-currency revenue growth and $93 million–$98 million of adjusted EBITDA. Management cited a Q4 currency headwind and an expected reversal of unusually strong preservation-services revenue; it also forecast PerClot’s departure to reduce 2027 revenue growth by about 2 percentage points and EBITDA growth by 4 points.
AMDS implants increased following U.S. PMA approval, but starter-set sales remain slow because hospitals face administrative hurdles around the roughly $100,000 upfront purchase. Management said it is working to ease those barriers, but expects account adoption to take time.
NEXUS preparations are progressing toward a planned U.S. launch on January 1, 2027, with surgeon interest, training, inventory-building, and sales-team expansion underway. Management expects sales to ramp gradually through 2027 and anticipates the combined business will be EBITDA-neutral for the year.
The ARTIZEN trial for the Arcevo LSA platform has enrolled 56 patients, with enrollment completion expected in mid-2027. Management expects to present initial results from the first 30 patients and, if the trial succeeds, anticipates FDA approval in 2029.

Artivion Price Performance

Shares of AORT stock traded down $5.09 during trading hours on Friday, reaching $20.23. 3,246,962 shares of the company were exchanged, compared to its average volume of 486,118. Artivion has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The stock’s fifty day moving average is $23.55 and its two-hundred day moving average is $28.98. The company has a market cap of $986.66 million, a price-to-earnings ratio of 43.67 and a beta of 1.31.

Analyst Ratings Changes

A number of research firms recently issued reports on AORT. Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Canaccord Genuity Group lowered their price objective on shares of Artivion from $40.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Finally, Citizens Jmp cut their target price on shares of Artivion from $48.00 to $42.00 and set a “market outperform” rating for the company in a research note on Friday. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Artivion presently has an average rating of “Moderate Buy” and a consensus price target of $40.57.

Get Our Latest Report on AORT

Insider Transactions at Artivion

In related news, CEO James P. Mackin sold 70,000 shares of Artivion stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the sale, the chief executive officer directly owned 877,275 shares of the company’s stock, valued at $25,397,111.25. The trade was a 7.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Andrew M. Green sold 11,480 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $24.97, for a total value of $286,655.60. Following the completion of the transaction, the senior vice president directly owned 40,160 shares in the company, valued at $1,002,795.20. The trade was a 22.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 90,460 shares of company stock worth $2,557,366 over the last 90 days. 6.30% of the stock is owned by insiders.

Key Headlines Impacting Artivion

Here are the key news stories impacting Artivion this week:

Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analysts’ estimates of about $121 million. The company also reported non-GAAP EPS of $0.08, above a consensus estimate of a $0.06 loss cited in one report. Artivion Q3 results
Positive Sentiment: Artivion forecast 2026 revenue of $484 million to $492 million and said it is preparing to launch its NEXUS product in January 2027, offering potential future growth catalysts. Revenue outlook and NEXUS launch
Neutral Sentiment: Citizens JMP lowered its price target to $42 from $48 but maintained a Market Outperform rating; the revised target still implies substantial upside from the cited share price. Citizens JMP recommendations
Negative Sentiment: Canaccord also cut its target, to $30, adding to concerns about analysts’ reassessment of the stock’s outlook. Canaccord price-target change
Negative Sentiment: Despite revenue growth, Artivion posted a $7.9 million GAAP net loss, and adjusted EBITDA fell 8% to $22.5 million. Zacks also reported that the $0.08 quarterly EPS missed its $0.11 estimate, highlighting that earnings expectations vary by source and may weigh on sentiment. Zacks earnings analysis

Artivion Company Profile

(Get Free Report)

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.